yes / Our overall aim is to develop a synthetic off-the-shelf alternative to human amniotic membrane which is currently used for delivering cultured limbal stem cells to the cornea in patients who suffer scarring of the cornea because of the loss of limbal stem cells. We have recently reported that both cultured cells and limbal explants grow well on electrospun Poly(D,L-lactide-co-glycolide) (PLGA) (44 kg/mol) with a 50:50 ratio of lactide and glycolide and sterilized with γ-irradiation. Prior to undertaking a clinical study our immediate aim now is to achieve long term storage of the membranes in convenient to use packaging. Membranes were electrospun from Poly(D,L-lactide-co-glycolide) (44 kg/mol) with a 50:50 ratio of lactide and glycolide and sterilized with γ-irradiation and then stored dry (with desiccant) for several months at -80°C and -20°C , Room temperature (UK and India), 37°C and 50°C. We explored the contribution of vacuum sealing and the use of a medical grade bag (PET/Foil/LDPE) to achieve a longer shelf life. Confirmation of membranes being suitable for clinical use was obtained by culturing tissue explants on membranes post storage. When scaffolds were stored dry the rate of breakdown was both temperature and time dependent. At -20°C and -80°C there was no change in fiber diameter over 18 months of storage, and membranes were stable for 12 months at 4°C while at 50°C (above the transition temperature for PLGA) scaffolds lost integrity after several weeks. The use of vacuum packaging and a medical grade bag both improved the storage shelf-life of the scaffolds. The impact of temperature on storage is summarized beneath. We report that this synthetic membrane can be used as an off-the-shelf or-out-of-the freezer alternative to the amniotic membrane for corneal regeneration.

The ultimate design of a microencapsulated AI dose is to continuously release sperm over a period of time in the female reproductive tract, thus alleviating the need for estrus detection. The objective of Trial 1 was to determine in vitro sperm release times for three microcapsule membranes. Semen was collected from four bulls, pooled, extended in 20% egg yolk TEST to a concentration of 80 = 10⁶ cells/ml, and encapsulated. Microcapsule membranes were constructed from isomers of polylysine: .1% poly-L-lysine (PLL), .1% poly-D-lysine (PDL), and a 50:50 mixture of the isomers (PLPD). Microcapsules were incubated at 37°C in a buffer containing .5% heparin or .5% trypsin and evaluated at 0.5, 1, 2, 4, 8, and 16 h post-encapsulation. For sperm encapsulated there were no significant differences in sperm motility. However, peak time of maximum sperm release differed between PLL and PDL membranes at 2 and 4 h of incubation. In Trial 2, sperm viability and microcapsule membrane stability were assessed post-thaw using PLL or PDL, two encapsulating temperatures (5°C or 23°C) and two times of glycerol addition (prior or post encapsulation at 5°C). Semen was extended to 80 = 10⁶ cells/ml and encapsulated. Capsules from all treatment combinations were incubated in .5% trypsin and evaluated as in Trial 1. In addition, motility was estimated at 1, 3, 6, and 9 h post-thaw. Motility from the unencapsulated control and capsules with glycerol addition prior to encapsulation, was superior (P < .05). Additionally, sperm release from capsules prepared at 5°C with glycerol addition post encapsulation was greater than all other treatments (P < .05). Time of peak sperm release for capsules was similar to the previous trial. There was a positive correlation between average capsule diameter and sperm release for both trials (P < .05). These data suggest that a combination of PLL and PDL capsules may complement each other in timing of sperm release and may be utilized in an inseminate mixture for extending the effective release in the female / Master of Science

Chemotherapy is one of the most important treatments for cancer. However, systemic toxicity, drug resistance and unstable kinetics of the drug in the blood are serious problems of chemotherapy. The use of biodegradable polymers for controlled release of anticancer drugs has gained popularity in recent years. Controlled release of drugs from polymeric carriers has some advantages such as improvement in the efficiency of treatment, reduction in systemic toxicity and prevention of the drug resistance that is developed by the cancer cells. In this study, poly(D,L-lactide-co-glycolide) microparticles were used as carriers for the controlled release of all-trans-Retinoic acid, tamoxifen, tamoxifen citrate and idarubicin. It was aimed to prepare a drug carrier system for controlled release of hydrophobic anticancer drugs. The empty and drug loaded poly (D,L-lactide-co-glycolide) microparticles were prepared by solvent extraction/evaporation technique with single emulsion (oil/water). Optimized microparticles were characterized by using inverted light microscopy and scanning electron microscopy to examine their morphology and sizes. Drug content of microparticles and the amount of released drug were determined spectrophotometrically. In vitro toxicity of the microparticles on MCF-7 human breast cancer cells was investigated. It was revealed that the microparticles were smooth and spherical in shape. Their sizes differed in the range of 2-20 &micro / m. atRA-loaded microparticles showed approximately 90% encapsulation efficiency and it was confirmed that changing in drug/polymer ratio affected the extend of drug content. Increase in drug content caused a slower release pattern. Moreover, although the empty microparticles caused some toxicity, atRA-loaded PLGA microparticles showed slight cell growth inhibition.

Breast cancer is the most frequent type of cancer seen in woman. Chemotherapy is one of the most important treatments for breast cancer. However, systemic toxicity, drug resistance and unstable kinetics of the drug in the blood are serious problems of chemotherapy. The use of biodegradable polymers for controlled release of anticancer drugs has gained popularity in recent years. Controlled release of anticancer drugs from polymeric carriers has some advantages such as improvement in the efficiency of treatment, reduction in systemic toxicity and prevention of the drug resistance that is developed by the cancer cells. In this study, it was aimed to prepare such a controlled release system for anticancer drugs which are used in breast cancer treatment by using biodegradable copolymer poly(D,L-lactide-co-glycolide) and to characterize in terms of morphology, size, drug content and drug release rate. In the first part of this study / empty and drug loaded poly (D,L-lactide-co-glycolide) microspheres were prepared. Two sets of empty poly(D,L-lactide-co-glycolide) microspheres were prepared by solvent evaporation technique with single emulsion (oil/water) to determine the effect of stirring rate on size of microspheres. Increase in stirring rate caused decrease in size of microspheres. Drug loaded poly(D,L-lactide-co-glycolide) microspheres were prepared for controlled release of anticancer drugs which are used in breast cancer treatment namely / 5-fluorouracil, methotrexate and tamoxifen by using solvent evaporation technique either with double emulsion (water/oil/water) or single emulsion (oil/water). In the second part of this study / empty and drug loaded microspheres were characterized. Inverted light microscopy and scanning electron microscopy were used to examine morphology and size of microspheres. Drug content of microspheres and amount of released drug were determined and drug release profile was obtained for each anticancer drug separetely.

Polylactide homopolymers with pendent carboxylic acid functional groups have been designed and synthesized to be studied as magnetite nanoparticle dispersion stabilizers. Magnetic nanoparticles are of interest for a variety of biomedical applications including magnetic field-directed drug delivery and magnetic cell separations. Small magnetite nanoparticles are desirable due to their established biocompatibility and superparamagnetic (lack of magnetic hysteresis) behavior. For in-vivo applications, it is important that the magnetic material be coated with biocompatible organic materials to afford dispersion characteristics or to further modify the surfaces of the complexes with biospecific moieties. The acid-functionalized silane endgroup was utilized as the dispersant anchor to adsorb onto magnetite nanoparticle surfaces and allowed the polylactide to extend into various solvents to impart dispersion stability. The homopolymers were complexed with magnetite nanoparticles by electrostatic adsorption of the carboxylates onto the iron oxide surfaces, and these complexes were dispersible in dichloromethane. The polylactide tailblocks extended into the dichloromethane and provided steric repulsion between the magnetite-polymer complexes. The resultant magnetite-polymer complexes were further incorporated into controlled-size nanospheres. The complexes were blended with poly(ethylene oxide-b-D,L-lactide) diblock copolymers to introduce hydrophilicity on the surface of the nanospheres with tailored functionality. Self-assembly of the PEO block to the surface of the nanosphere was established by utilizing an amine terminus on the PEO to react with FITC and noting fluorescence. / Ph. D.

Les nanoparticules polymériques biodégradable (NPs) sont apparues ces dernières années comme des systèmes prometteurs pour le ciblage et la libération contrôlée de médicaments. La première partie de cette étude visait à développer des NPs biodégradables préparées à partir de copolymères fonctionnalisés de l’acide lactique (poly (D,L)lactide ou PLA). Les polymères ont été étudiés comme systèmes de libération de médicaments dans le but d'améliorer les performances des NPs de PLA conventionnelles. L'effet de la fonctionnalisation du PLA par insertion de groupements chimiques dans la chaîne du polymère sur les propriétés physico-chimiques des NPs a été étudié. En outre, l'effet de l'architecture du polymère (mode d'organisation des chaînes de polymère dans le copolymère obtenu) sur divers aspects de l’administration de médicament a également été étudié. Pour atteindre ces objectifs, divers copolymères à base de PLA ont été synthétisés. Plus précisément il s’agit de 1) copolymères du poly (éthylène glycol) (PEG) greffées sur la chaîne de PLA à 2.5% et 7% mol. / mol. de monomères d'acide lactique (PEG2.5%-g-PLA et PEG7%-g-PLA, respectivement), 2) des groupements d’acide palmitique greffés sur le squelette de PLA à une densité de greffage de 2,5% (palmitique acid2.5%-g-PLA), 3) de copolymère « multibloc » de PLA et de PEG, (PLA-PEG-PLA)n. Dans la deuxième partie, l'effet des différentes densités de greffage sur les propriétés des NPs de PEG-g-PLA (propriétés physico-chimiques et biologiques) a été étudié pour déterminer la densité optimale de greffage PEG nécessaire pour développer la furtivité (« long circulating NPs »). Enfin, les copolymères de PLA fonctionnalisé avec du PEG ayant montré les résultats les plus satisfaisants en regard des divers aspects d’administration de médicaments, (tels que taille et de distribution de taille, charge de surface, chargement de drogue, libération contrôlée de médicaments) ont été sélectionnés pour l'encapsulation de l'itraconazole (ITZ). Le but est dans ce cas d’améliorer sa solubilité dans l'eau, sa biodisponibilité et donc son activité antifongique. Les NPs ont d'abord été préparées à partir de copolymères fonctionnalisés de PLA, puis ensuite analysés pour leurs paramètres physico-chimiques majeurs tels que l'efficacité d'encapsulation, la taille et distribution de taille, la charge de surface, les propriétés thermiques, la chimie de surface, le pourcentage de poly (alcool vinylique) (PVA) adsorbé à la surface, et le profil de libération de médicament. L'analyse de la chimie de surface par la spectroscopie de photoélectrons rayon X (XPS) et la microscopie à force atomique (AFM) ont été utilisés pour étudier l'organisation des chaînes de copolymère dans la formulation des NPs. De manière générale, les copolymères de PLA fonctionnalisés avec le PEG ont montré une amélioration du comportement de libération de médicaments en termes de taille et distribution de taille étroite, d’amélioration de l'efficacité de chargement, de diminution de l'adsorption des protéines plasmatiques sur leurs surfaces, de diminution de l’internalisation par les cellules de type macrophages, et enfin une meilleure activité antifongique des NPs chargées avec ITZ. En ce qui concerne l'analyse de la chimie de surface, l'imagerie de phase en AFM et les résultats de l’XPS ont montré la possibilité de la présence de davantage de chaînes de PEG à la surface des NPs faites de PEG-g-PLA que de NPS faites à partie de (PLA-PEG-PLA)n. Nos résultats démontrent que les propriétés des NPs peuvent être modifiées à la fois par le choix approprié de la composition en polymère mais aussi par l'architecture de ceux-ci. Les résultats suggèrent également que les copolymères de PEG-g-PLA pourraient être utilisés efficacement pour préparer des transporteurs nanométriques améliorant les propriétés de certains médicaments,notamment la solubilité, la stabilité et la biodisponibilité. / Biodegradable polymeric nanoparticles (NPs) have emerged as promising drug delivery carriers for the controlled drug release and targeting. The first part of this study aimed to develop biodegradable NPs from functionalized copolymers of poly (D,L-Lactide) (PLA). Those copolymers were explored as drug delivery systems in attempt to improve the drug delivery performance of conventional PLA NPs. The effect of PLA functionalization (insertion of chemical substituents onto PLA backbone) on the physicochemical properties of the obtained NPs was investigated. Moreover, the effect of polymer architecture (mode of organization of polymer chains in the resultant copolymer) on various drug delivery aspects was also studied. To reach those goals, various PLA based copolymers namely poly(ethylene glycol) (PEG) grafted on PLA backbone at 2.5% & 7% mol/mol of lactic acid monomers (PEG2.5%-g-PLA and PEG7%-g-PLA, respectively), palmitic acid grafted on PLA backbone at 2.5% grafting density (palmitic acid2.5%-g-PLA), and multiblock copolymer of PLA and PEG, (PLA-PEG-PLA)n were synthesized. In the second part, the effect of different PEG grafting densities over PLA backbone on the properties of PEG-g-PLA NPs either physicochemical or biological properties was investigated to reveal the optimal PEG grafting density required to develop stealth particles (long circulating NPs). Finally, functionalized PEG/PLA copolymers that showed the most satisfactory results in terms of various drug delivery aspects, such as size and size distribution, surface charge, drug loading, and controlled drug release were selected for encapsulation of itraconazole (ITZ) to improve its aqueous solubility, bioavailability and hence its antifungal activity. NPs were first prepared from functionalized PLA copolymers then analyzed for their major physicochemical parameters such as encapsulation efficiency, size and size distribution, surface charge, thermal properties, surface chemistry, % poly(vinyl alcohol) (PVA) adsorbed at the surface of NPs, and drug release pattern. Surface chemistry analysis using x-ray photoelectron spectroscopy (XPS), and atomic force microscopy (AFM) phase imaging were used to study the chain organization behavior of each functionalized copolymer during NPs formulation. Generally speaking, functionalized PEG/PLA copolymers showed improved drug delivery behavior in terms of narrow size and size distribution, enhanced loading efficiency, less plasma protein adsorption onto their surfaces and less macrophage uptake, and finally better antifungal activity for ITZ loaded NPs. For the surface chemistry analysis, AFM phase imaging and XPS studies revealed the possibility of existence of more PEG chains at the surface of PEG-g-PLA NPs than (PLA-PEG-PLA)n during NPs formation. Our results demonstrate that properties of PLA-based NPs can be tuned by proper selection of both polymer composition and polymer architecture. Results also suggest that PEG-g-PLA copolymers could be used efficiently as a nanocarrier to improve various drug properties e.g. solubility, stability, and bioavailability.

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Regulation of gene expression using small interfering RNA (siRNA) is a promising strategy for research and treatment of numerous diseases. However, siRNA cannot easily cross the cell membrane due to its inherent instability, large molecular weight and anionic nature. For this reason, a carrier that protects, delivers and unloads siRNA is required for successful gene silencing. The goal of this research was to develop a potential siRNA delivery system for in vitro and in vivo applications using cationic polymers, chitosan and polyethylenimine (PEI), poly(ethylene glycol) (PEG), mannose, and poly(D,L-lactic-co-glycolic acid) (PLGA). Furthermore, the delivery system was constructed in two different ways to explore the effect of mannose location in the structure. In the first approach, mannose and PEG were directly conjugated to the chitosan/PEI backbone, while mannose was connected to the chitosan/PEI backbone through PEG spacer in the second approach. First, the ability of modified chitosan polymers to complex and deliver siRNA for gene silencing was investigated. Despite the modified chitosan polymers successfully formed nanoplexes with siRNA, entered target cells and reduced cytotoxicity of unmodified chitosan, they showed limited gene silencing efficiency. For this reason, modified PEIs were examined to improve in vitro gene knockdown. The modified PEI polymers also complexed with siRNA and facilitated endocytosis of the nanoplexes. In addition, the modifications reduced inherent cytotoxicity of unmodified PEI without compromising the gene silencing efficiency on both mRNA and protein levels. Interestingly, we found that complexation of siRNA with PEI-PEG-mannose resulted in higher cell uptake and gene silencing than complexes made with mannose-PEI-PEG. Finally, the effect of sustained release of the mannosylated pegylated PEI/siRNA nanoplexes on gene silencing was tested by encapsulating the nanoplexes within PLGA microparticles. The modified PEIs enhanced the entrapment efficiency of siRNA into the particles and resulted in reduced initial burst followed by sustained release. Incorporating the modified PEIs increased cellular uptake of siRNA, whereas it did not enhance in vitro gene knockdown efficiency due to the sustained release properties. The modified PEIs reduced the in vitro cytotoxicity and in vivo hepatotoxicity of the PLGA microparticles. In addition, encapsulating the nanoplexes into PLGA microparticles further reduced the cytotoxicity of PEI. Throughout the study, the second structure was proven more efficacious than the first structure in cellular uptake, gene silencing, siRNA encapsulation, and sustained release. We have developed novel polymeric siRNA delivery systems that enhance delivery efficiency and cellular uptake of siRNA. They have great potential for utility as a long-acting siRNA delivery system in biomedical research.

The use of various biodegradable polymers for the improvement of different controlled and long-lasting drug release systems is an active research area in recent years. The application of different metal prostheses, especially titanium based ones, to the human body is also very common. A most important disadvantage of these prostheses is the risk of infection at the application areas that necessitates the removing of the prosthesis with a second surgical operation and reapplication of it after recovery. One of the best ways to solve this problem is to render metal prostheses infection free with controlled and sustainable drug (antibiotic) release systems. The long term sustained release of relevant antibiotics from the various biodegradable polymer coated metal implants is studied in this thesis. Virtual fatigue analysis and drug loading capacities of titanium and stainless steel samples with different surface pattern and modifications were studied. Various biodegradable polymer and drug combinations were examined and used for coating of metal prosthesis. The aim is to design polymer-drug coated metal implants that are capable of releasing a feasible amount of drug up to a period of at least 1 month. Various coating techniques and surface modifications were also employed to improve the adhesional properties of the drug containing polymers. Their adhesion abilities on the metal substrates were tested by Lap-shear and T-peel tests. Polymer degradation kinetics was followed by viscosity studies. Calibration lines for different drugs were obtained and drug releases on different systems were followed by using UV spectroscopy and microbial antibiotic sensitivity tests. Among the techniques applied to prevent fast release of drugs initially, the coatings of Vancomycin absorbed &amp / #946 / -TCP (&amp / #946 / -tricalcium phosphate) homogeneously distributed in poly(D,L-lactide-co-glycolide) solution in chloroform followed by an inert coating with poly(L-lactide) system proved to be feasible. By this technique, initial burst release was minimized and drug release from implants lasted nearly 2 months. Multiple coatings on polymer plus drug coating layer also gave promising results. In vivo studies on dorsal muscles of native rabbits with antibiotic loaded implants gave no negative effect on the surrounding tissues with high compatibility free of infection.

This research centers on the fabrication, characterization, and engineering of inverse opal scaffolds, a novel class of three-dimensional (3D) porous scaffolds made of biocompatible and biodegradable polymers, for applications in tissue engineering and regenerative medicine. The unique features of an inverse opal scaffold include a highly ordered array of pores, uniform and finely tunable pore sizes, high interconnectivity, and great reproducibility. The first part of this work focuses on the fabrication and functionalization of inverse opal scaffolds based on poly(D,L-lactic-co-glycolic acid) (PLGA), a biodegradable material approved by the U.S. Food and Drug Administration (FDA). The advantages of the PLGA inverse opal scaffolds are also demonstrated by comparing with their counterparts with spherical but non-uniform pores and poor interconnectivity. The second part of this work shows two examples where the PLGA inverse opal scaffolds were successfully used as a well-defined system to investigate the effect of pore size of a 3D porous scaffold on the behavior of cell and tissue growth. Specifically, I have demonstrated that i) the differentiation of progenitor cells in vitro was dependent on the pore size of PLGA-based scaffolds and the behavior of the cells was determined by the size of individual pores where the cells resided in, and ii) the neovascularization process in vivo could be directly manipulated by controlling a combination of pore and window sizes when they were applied to a mouse model. The last part of this work deals with the novel application of photoacoustic microscopy (PAM), a volumetric imaging modality recently developed, to tissue engineering and regenerative medicine, in the context of non-invasive imaging and quantification of cells and tissues grown in PLGA inverse opal scaffolds, both in vitro and in vivo. Furthermore, the capability of PAM to monitor and quantitatively analyze the degradation of the scaffolds themselves was also demonstrated.